Table 2.

Administration/dosage regimens for approved RRMS treatments

Disease-modifying treatment	Route of administration	Adult dose
Alemtuzumab [42]	IV infusion	12 mg/day for 5 consecutive days, then 12 mg/day for 3 consecutive days every 12 months for a total of up to four courses
Cladribine [41]	PO	10–20 mg/day for 4–5 days in week 1 and 2 of months 1 and 2 in years 1 and 2
Dimethyl fumarate [40]	PO	120–240 mg twice daily
Fingolimod [43]	PO	0.5 mg once daily
Glatiramer acetate [45]	SC	20 mg once daily or 40 mg three times weekly
Interferon β-1a [32]	IM	30 μg once a week
Interferon β-1a [38]	SC	22–44 μg three times weekly
Interferon β-1b [33, 34]	SC	62.5–250 μg every other day
Natalizumab [35]	IV infusion	300 mg every 4 weeks
Ocrelizumab [37]	IV infusion	300 mg then 300 mg 2 weeks later, then 600 mg every 6 months
Ofatumumab [36]	SC	20 mg per week for first three doses and then 20 mg monthly
Pegylated interferon β- 1a [39]	SC or IM	63 mg on day 1, 94 mg on day 14, and then 125 mg on day 28 and every 2 weeks thereafter
Teriflunomide [44]	PO	14 mg once daily

IM intramuscular, IV intravenous, PO oral, SC subcutaneous